Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Asset Writedowns and Impairment (2018 - 2020)

Outlook Therapeutics (OTLK) has disclosed Asset Writedowns and Impairment for 3 consecutive years, with $104296.0 as the latest value for Q2 2020.

  • Quarterly Asset Writedowns and Impairment rose 104.8% to $104296.0 in Q2 2020 from the year-ago period, while the trailing twelve-month figure was $8.9 million through Jun 2020, changed N/A year-over-year, with the annual reading at $527624.0 for FY2020, 95.32% down from the prior year.
  • Asset Writedowns and Impairment for Q2 2020 was $104296.0 at Outlook Therapeutics, down from $423328.0 in the prior quarter.
  • The five-year high for Asset Writedowns and Impairment was $8.3 million in Q3 2019, with the low at $50927.0 in Q2 2019.
  • Average Asset Writedowns and Impairment over 3 years is $2.0 million, with a median of $492531.5 recorded in 2019.
  • Peak annual rise in Asset Writedowns and Impairment hit 104.8% in 2020, while the deepest fall reached 24.64% in 2020.
  • Over 3 years, Asset Writedowns and Impairment stood at $2.3 million in 2018, then soared by 253.62% to $8.3 million in 2019, then plummeted by 98.74% to $104296.0 in 2020.
  • According to Business Quant data, Asset Writedowns and Impairment over the past three periods came in at $104296.0, $423328.0, and $8.3 million for Q2 2020, Q1 2020, and Q3 2019 respectively.